Company intelligence / Profile preview

Hybiome

Suzhou, Jiangsu, China

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Hybiome develops, manufactures, and markets CFDA/NMPA-cleared automated chemiluminescence immunoassay analyzers and reagent kits (about 80 assay parameters) widely installed (~1,000 instruments) in mainly mid-size Chinese hospitals; its assays demonstrate analytical performance comparable to leading international systems and are commercially used for routine clinical diagnostics including oncology and infectious disease markers.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DeviceDiagnostic assaySoftware
Industry: Protein Biomarker Diagnostics

Partnerships

bioMérieux (majority shareholder and strategic partner in immunoassays and China diagnostics market)

Beyond the preview

Go deeper on Hybiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hybiome.

Explore the full profile